Coloplast ASCLPBF 72 EBIT per Share is $3.11 as of Mar. 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.99 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Coloplast AS ranks worse than 61.45% on this metric.
Coloplast AS's EBIT per Share for the
three
months ended in Mar. 2026 was $-0.73.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $3.11.
During the past 12 months, the average EBIT per Share Growth Rate of Coloplast AS was 0.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 1.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 3.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 5.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Coloplast AS's EBIT per Share or its related term are showing as below:
CLPBF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -4.1 Med: 6.8 Max: 39.2
Current: 1.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Coloplast AS was 39.20% per year. The lowest was -4.10% per year. And the median was 6.80% per year.
CLPBF's 3-Year EBIT Growth Rate is ranked worse than 61.45% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs CLPBF: 1.60
Coloplast AS's EBIT for the
three
months ended in Mar. 2026 was $-163 Mil.
Coloplast AS (OTCPK:CLPBF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Coloplast AS EBIT per Share Related Terms
Coloplast AS EBIT per Share Historical Data
* Premium members only.
The historical data trend for Coloplast AS's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBF) has a EBIT per Share of $3.11 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Coloplast AS and its competitors. According to the industry distribution chart, Coloplast AS ranks #424 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 61.4%.
Is Coloplast AS's EBIT per Share too high?
Coloplast AS's current EBIT per Share is $3.11. The Medical Devices & Instruments industry median EBIT per Share is 9.60. Coloplast AS's value of $3.11 is 67.6% below this industry median. Based on the distribution chart, Coloplast AS ranks #424 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's EBIT per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #424 out of 690 companies for EBIT per Share. This places Coloplast AS in the lower half of its industry. The industry median EBIT per Share is 9.60. Coloplast AS's value of $3.11 is 67.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current EBIT per Share of $3.11 is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current EBIT per Share is $3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.99, compared to a current price of $56.90 — trading 55.2% below its estimated fair value. The current EBIT per Share is $3.11 and 67.6% below the Medical Devices & Instruments industry median of 9.60. Coloplast AS's overall GF Score™ is 72/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current EBIT per Share is $3.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $56.90 is trading 55.2% below its estimated GF Value™ of $126.99.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
EBIT per Share: $3.11
GF Value™: $126.99 vs. price of $56.90 (55.2% below fair value)
Industry Position: 67.6% below the Medical Devices & Instruments median (#424 of 690)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
